Zacks Investment Research has shares of Icon (NASDAQ: ICLR) from a clearing classification to a buy-rating in a research report released on Thursday 9 August. They currently have a target price of $ 163.00 on the shares of the medical research company.
According to Zacks, "ICON plc is a global full-service clinical research organization, providing contract clinical research services to the pharmaceutical industry worldwide."
Other analysts have also published research reports about the stock. Robert W. Baird confirmed a buy rating and set a price target of $ 154.00 on Icon shares in a research report on Thursday, July 26. SunTrust Banks raised its price target on Icon shares to $ 153.00 and gave the company a buy rating in a research report on Thursday, July 26. BidaskClub raised shares of Icon from a hold rating to a buy rating in a research report on Thursday, May 3. Jefferies Financial Group raised its price target on Icon shares to $ 150.00 and gave the company a buy rating in a research report on Friday, June 1. Finally, Mizuho set a target price of $ 146.00 on Icon and gave the company a hold rating in a research report on Monday, August 6th. Two research analysts have assessed the shares with a hold rating and ten have assigned a buy-rating to the company's shares. The share has a consensus rating of buying and an average price target of $ 143.60.
Shares of Icon shares opened Thursday at $ 144.49. The company has a market capitalization of $ 7.83 billion, a PE ratio of 26.81, a P / E / G ratio of 2.06 and a beta of 0.40. The icon has a 1-year low of $ 101.22 and a 1-year high of $ 149.69. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.10 and a current ratio of 2.10.
Icon (NASDAQ: ICLR) last published its results on Wednesday 25 July. The medical research firm reported $ 1.31 earnings per share for the quarter, with the Thomson Reuters consensus estimate of $ 1.48 with ($ 0.17) being missed. The company had sales of $ 641.60 million for the quarter compared with analyst estimates of $ 618.64 million. Icon had a return on equity of 26.35% and a net margin of 13.69%. The company's revenue for the quarter increased by 48.9% year-on-year. In the same quarter of the previous year, the company earned $ 1.34 earnings per share. Analysts expect Icon to publish 6.08 per share for the current fiscal year.
Several large investors have recently bought and sold shares of the company. Marietta Investment Partners LLC increased the share in Icon in the second quarter by 18.3%. Marietta Investment Partners LLC now owns 2,472 shares of the medical research company valued at $ 328,000, after the acquisition of 382 additional shares in the last quarter. Fisher Asset Management LLC increased the share in Icon in the second quarter by 1.9%. Fisher Asset Management LLC now owns 21,316 shares of the medical research company valued at $ 2,825,000 after acquiring 400 additional shares in the last quarter. Cambiar Investors LLC grew its share in Icon in the second quarter by 9.9%. Cambiar Investors LLC now owns 4,498 shares of the medical research company's business worth $ 596,000 after the acquisition of 405 additional shares in the last quarter. CIBC Private Wealth Group LLC increased the share in Icon by 0.5% in the second quarter. CIBC Private Wealth Group LLC now owns 80,342 shares of the medical research business to the value of $ 10,648,000 after the acquisition of 405 additional shares in the last quarter. Finally, Comerica Bank increased its stake in Icon by 9.1% in the second quarter. Comerica Bank now owns 5,872 shares of the medical research company's shares worth $ 806,000 after acquiring an additional 490 shares in the last quarter. Institutional investors and hedge funds hold 90.40% of the company's shares.
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology and medical device industries in Ireland, the rest of Europe, the United States and internationally. It specializes in the strategic development, management and analysis of programs that support different stages of the clinical development process, from composite selection to clinical Phase I-IV studies.
Featured article: closed-end investment funds
Receive a free copy of the Zacks research report on Icon (ICLR)
Visit Zacks.com for more information about research offers from Zacks Investment Research
Receive news and ratings for Icon Daily – Enter your e-mail address below to receive a concise, daily summary of the latest news and reviews from analysts for Icon and related companies with the FREE daily e-mail newsletter from MarketBeat.com.